Draft a hepatitis C elimination program: screening cohorts, reflex RNA, treatment…
- User
Draft a hepatitis C elimination program: screening cohorts, reflex RNA, treatment models, reinfection prevention, and registry.
- Assistant
Hepatitis C Elimination Program Draft
Program Overview
This draft outlines a comprehensive Hepatitis C Virus (HCV) elimination program aligned with WHO targets: 90% diagnosis, 90% treatment coverage, and 90% sustained virologic response (SVR) by 2030. The program employs a "micro-elimination" strategy, focusing on high-prevalence cohorts, simplified diagnostics, direct-acting antiviral (DAA) treatment, prevention, and data tracking. Implementation requires multi-sectoral collaboration (health departments, prisons, addiction services, primary care), funding for DAAs/point-of-care (POC) tests, and a centralized registry.
Goals:
- Screen 95% of priority cohorts.
- Achieve >90% linkage to reflex RNA confirmation and treatment.
- Reduce new infections by 80% through prevention.
- Verify elimination via registry surveillance.
Budget Estimate (per 100,000 population): 2M/year ongoing.
1. Screening Cohorts
Universal birth-cohort screening combined with risk-based targeting to maximize yield.
Cohort Rationale Screening Method Target Coverage Frequency Baby Boomers (born 1945-1965) 75% of US chronic cases; often undiagnosed. One-time opt-out screening in primary care/EDs. 95% by Year 3. Once. People Who Inject Drugs (PWID) 40-60% prevalence; ongoing transmission. Routine in needle exchange, opioid treatment programs (OTP), harm reduction sites. Annual. Every 6-12 months. Incarcerated Individuals Prevalence 10-40%; high reinfection risk post-release. Universal entry/exit screening in prisons/jails. 100%. Entry + exit. HIV/Hepatitis B Co-infected 20-30% HCV co-prevalence. Reflex HCV screen at HIV diagnosis/annual follow-up. 100%. Annual. Hemodialysis Patients 5-10% prevalence. Annual screening. 100%. Annual. High-Risk Groups (e.g., MSM, transgender, migrants from endemic areas) Behavioral/epidemiologic risks. Targeted campaigns via clinics/NGOs. 90%. Risk-based. General Population (opportunistic) EDs, primary care, blood donors. Opt-out in routine labs. 50% by Year 5. Once. Implementation: Free POC antibody tests (e.g., OraQuick). Train 1,000 lay providers. Mobile units for PWID/homeless.
2. Reflex RNA Testing
Streamline diagnosis to enable same-day treatment initiation (treat-anywhere model).
- Protocol: Positive antibody → automatic reflex to quantitative HCV RNA PCR (POC devices like Xpert HCV Viral Load, turnaround <1 hour).
- Threshold: RNA >1,000 IU/mL confirms active infection; initiate treatment if eligible.
- Venues: Primary care, prisons, OTPs, harm reduction sites equipped with POC machines (target: 200 sites).
- Linkage: 95% same-day result delivery via SMS/app. Nurse navigators for positives (contact within 24 hours).
- Cost: $20-50/test; bulk procurement for scale.
- Quality: Quarterly proficiency testing; integrate with EHRs.
Flowchart:
Antibody Screen (+) → Reflex RNA ├── RNA (-) : HCV-resolved, educate/prevent └── RNA (+) : Genotype (if needed) → Treat3. Treatment Models
Pan-genotypic DAAs (e.g., glecaprevir/pibrentasvir, 8-12 weeks, >95% cure). Decentralized, nurse-led.
Model Description Target Population Provider Monitoring Test-and-Treat (POC) Same-day screen/treat at site. PWID, prisons, EDs. Nurses/Lay providers (task-shifting). SVR test at 12 weeks post-treatment (POC RNA). Primary Care Simplified Rx after reflex RNA; 1-2 visits. Baby boomers, general. GPs with e-consult to hepatologists. Telehealth follow-up. Community DAA Hubs Fixed/mobile sites with pharmacy pickup. High-risk/remote. Pharmacists. App-based adherence reminders. Incarcerated Treat pre-release; linkage post-release. Prisons. On-site teams. 90-day Rx bridge. Eligibility: All non-cirrhotic; decompensated via FibroScan/e-consult. No sobriety requirement. Free DAAs via patient assistance/national tender.
Metrics: >90% treatment initiation within 3 months of diagnosis; >95% SVR.
4. Reinfection Prevention
Zero new infections via harm reduction and education.
-
Core Interventions:
Strategy Components Target Harm Reduction Needle/syringe programs (NSP): 200% exchange ratio; opioid substitution therapy (OST) scale-up. PWID: 80% coverage. Vaccination/PEP No vaccine; promote HBV vaccine (HCV proxy). Post-exposure prophylaxis research pilots. High-risk: 90%. Behavioral Peer education on risks; condom promotion for sexual transmission. PWID/MSM: Annual sessions. Micro-Elimination Clearance campaigns in prisons/NSPs until <1% prevalence. Ongoing. Surveillance Annual rescreening; partner notification. All cured: 1-year rescreen. -
Funding: Integrate with existing HIV/Harm Reduction budgets; $1M/year for NSP expansion.
-
Success Metric: Incidence <0.1/100 person-years in PWID.
5. Registry and Surveillance
Centralized, real-time database for elimination verification.
-
Platform: National HCV Registry (cloud-based, HL7-integrated EHRs).
-
Data Elements:
Category Fields Demographics Age, sex, risk factors, location. Diagnostics Antibody/RNA dates/results, genotype. Treatment DAA regimen, start/end dates, adherence. Outcomes SVR (12+ weeks post), reinfection, HCC/death. Prevention NSP/OST enrollment, rescreens. -
Features:
- Unique patient ID for deduplication.
- Dashboards: Cascade metrics (screened/diagnosed/treated/cured).
- Alerts: Reinfection (>6 months post-SVR), treatment failure.
- Reporting: Annual WHO submissions; incidence modeling.
- Privacy: De-identified for research; opt-out minimal.
-
Governance: Ministry-led with ethics board. Mandatory reporting for positives.
-
Rollout: Pilot in 2 regions (Year 1), national (Year 2).
Implementation Timeline and Evaluation
Phase Timeline Milestones Planning Months 1-3 Cohort mapping, POC procurement, registry build. Pilot Months 4-12 2 high-prevalence sites; 10,000 screened. Scale-Up Years 2-3 National rollout; 90% cascade. Sustain Year 4+ <5 new cases/year/100k; WHO verification. Evaluation: Independent audits; cost-effectiveness modeling (ICER <$1,000/DALY averted).
Risks/Mitigation: Stigma (anti-discrimination campaigns); supply (DAAs stockpiled); funding (advocacy for grants).
This draft is adaptable; contact for customization.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.